Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces its full unaudited results for the year ended 31 March 2020. As announced on 15 June 2020, the Company has been granted an extension to the deadline for filing its audited consolidated accounts for the 31 March 2020 year end to 31 December 2020, based on regulatory guidance solely in relation to the ongoing COVID-19 pandemic.
Post Period End
Q1 and current trading update
Annual General Meeting
The Company’s AGM will be held at 3 Robroyston Oval, Nova Business Park, Glasgow, G33 1AP on 23 September 2020 at 11:00am. As audited financial statements will not be presented due to the delay in the audit due to COVID-19, the primary objective of this meeting will be to re-elect directors by rotation and to authorise the directors to fix the auditor’s remuneration.
Jamal Rushdy, Chief Executive Officer of Collagen Solutions, commented: “We are pleased with the performance and resilience of our business last year, having achieved double-digit growth through the first 11 months up until the COVID-19 shock in March, and quickly rebounding with a strong first quarter with a full order book on track to deliver growth in the current year.”
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
I am pleased to present my first report as Chairman of Collagen Solutions for the year ended 31 March 2020.
The Company delivered revenue and other income of £4.46 million, a slight decrease of 1% over the prior year, and revenue excluding other income of £4.01 million, reflecting a 3% decline versus the prior year. The Company had a strong first
half of the year, with 14% revenue growth. The second half of the year slowed due to capacity constraints in its Glasgow plant, yet maintained overall year-to-date double-digit growth up until the last month of the financial year when it experienced
COVID-19 impacts to the business as well.
The COVID-19 year-end challenges we experienced have abated for now, our trading through the first quarter is ahead of our expectations, and operational improvements in our Glasgow operations are showing positive results. We remain encouraged by our strong order book and continued strength of demand to support our optimistic view of the year, yet also cautious in managing our cash position given the general ongoing uncertainties in the current business environment.
The Company’s financial position was significantly bolstered by a successful equity raise in June 2019 of £5.96 million at a 23.5% premium to the market price. This included a £4.18 million strategic anchor investment from Rosen's Diversified
Inc. (“RDI”). The strategic investment among other benefits increased our access to animal tissue-related biomedical products via a concurrent supply agreement with Scientific Life Solutions (a subsidiary of RDI) for the supply of tissue.
The funding also helped fuel our growth and facilities expansion to support higher volumes and contract manufacturing.
Two write-downs in the financial year have impacted our reported performance, the first due to an inability of a customer to settle its debts to date and the other due to the recognition of losses which are anticipated to be incurred related to the development
phase of a specific contract. We believe the latter will put us on a better financial footing with this important contract for the future and the commercial view of the value of the contract overall in the long term remains positive.
In the last month of the last financial year, we saw the early impact of COVID-19. We therefore at the start of our current financial year prudently enacted several initiatives to prioritise liquidity and the preservation of cash to enhance our financial
position in response to uncertain market conditions. These included the renegotiation of the Norgine Ventures debt, securing £0.32 million in government-backed grants and loans, implementing temporary pay cuts for executive team and board
members, accessing Scottish Enterprise R&D grant monies, and undertaking other cuts and delays of certain investment decisions.
Strategic Review and Sale Process
On 16 April 2020 we announced a strategic review and formal sale process and provided a further update on 18 May 2020 that the Company received indications of interest in respect of (i) a purchase of the Company as a whole (ii) a purchase or investment
in a part of the business of the Company and (iii) a refinancing of the Company. The Company has engaged with these relevant parties, and is in continued discussions with a view to optimising value for shareholders. A further statement will be
made by the Company in respect to the strategic review and formal sale process when appropriate.
Board and Management
I am honoured to have succeeded David Evans as Chairman last year. With the addition of Wade Rosen to our Board following Rosen’s Diversified Inc’s strategic investment, we also reduced the size of the Board to help ensure focus and support for the executive management team. We are confident in the management team we have assembled and appreciative of their resilience and decisive actions through the COVID-19 crisis taken to ensure we keep employees and their families safe whilst continuing to serve our customers who are serving the critical ongoing needs of patients.
Focus for Financial Year 2021
Our key targets for the current year are as follows:
Our order book and sales through the first quarter are currently worth in excess of £4 million, which provides added confidence for the next nine months.
Additionally, our customer’s surgical product end-markets appear to be recovering from the decline in non-emergency or elective procedure volumes, and our customer’s demand for our services and biomaterials products have not declined. The Company and our markets have been tested but are showing resilience. We continue to believe the underlying clinical demand for our products will remain strong in the medium-to-long term, and the Company is well positioned in these markets.
On behalf of the Board I would like to thank our shareholders, employees, and customers for their continued support.
Chris Brinsmead CBE
31 July 2020
I am pleased with the performance and resilience of our business last year, having achieved double-digit growth through the first 11 months up until the COVID-19 shock in March, and quickly rebounding with a strong first quarter with a full order book
on track to deliver growth in the current year.
Revenue and other income for the year was £4.46 million, including £4.01 million in sales and £0.45 million in other income. This represents a small decline of 1% on prior year overall, with 3% revenue decline.
We added nine new customer agreements during the year and are continuing to add higher-value customers, including one new blue-chip customer signing up for a development agreement for an orthopaedic product. New customer agreements came from all our geographies
with four in North America, three in EMEA and two in Asia Pacific.
Our tissue business category posted very strong growth of 58% to £1.4 million, driven by an existing blue chip customer ramping up their business and solidified by a new long-term supply agreement to support their growth with larger contracted volumes, as well as a new customer from FY 2019 that also ramped up their business with us that came as a result of our diversification of products in FY 2019. The tissue segment continues to bring on new customer and grow with existing customers.
Our development category grew 10%, driven by several new customer projects and ongoing milestones from existing customer projects. The category represented 28% of revenue, and we believe a leading indicator of future contract manufacturing growth as these
products gain regulatory approvals and are successfully launched by our customers. Contract manufacturing was flat and still in its early days with few customers in launch, but already representing 12% of revenue.
We experienced challenges with the March COVID-19 impacts and capacity constraints that contributed to a 34% decline in the collagen supply business. Anticipating the capacity constraints, earlier in the year we made a £0.5 million investment in
expanding our manufacturing capacity and also a focus on our people and processes in our Glasgow plant to support our increased demand and work through our backlogs.
Geographically, revenue from North America increased by 11% to £2.92 million driven by tissue revenue as described above. The EMEA region declined 41% to £0.35 million, reflecting some lumpiness in milestones with a customer that is just beginning contract manufacturing and is now ramping up activities. Asia Pacific also declined by 20%, and was most impacted by the collagen supply constraints mentioned above.
Our product development focus has shifted towards customer-driven projects and associated milestones. In FY 2020, the product development team supported delivery of £733k of development revenue across multiple active customer projects. The
team also supports the commercial team’s efforts to bring in new customer agreements related to product development, with an aim to transition to contract manufacturing once approved.
In addition, the team also continues to advance the CE mark application for ChondroMimetic®. As previously announced, the European Parliament on 17 April 2020 voted to defer for a year until 26 May 2021 the Medical Devices Regulation (MDR) from taking effect. This postponement will provide us additional time to submit under the current Medical Devices Directive (MDD) and should therefore avoid potential increased costs and timelines associated with having to re-submit under the MDR. We have made progress answering the higher-risk clinical data and animal tissue questions and continue to work through remaining technical file questions that require additional, but customary, updated validation data to gain final approval.
Operations and Infrastructure
Our major operational initiative in FY 2020 was to improve capacity at our Glasgow, Scotland plant with an investment of c.£0.5 million in freeze drier capacity and clean room footprint. This initiative was substantially completed in the second
half of FY 2020, with process validations and improvements carrying over into the first quarter of FY 2021. While operations were somewhat hampered by reduce staffing levels due to COVID-19 and bringing the new capacity on-line, the investments are
now showing results and are on track to deliver against the strong order book we have thus far in FY 2021, with in excess of £4 million of orders in hand or already delivered.
We continue to value feedback from our employees and perform semi-annual surveys and other feedback opportunities to measure employee engagement and take action where necessary. We have seen engagement scores improve during FY 2021, we believe because we take the feedback seriously and implement changes and actions our employees tell us are important to improve service levels to our customers and enable them to excel.
The management team is proud of our global organisation’s resilience and enthusiasm for customer delivery. We are energised by the momentum throughout nearly all of last year and strengthened by our perseverance and actions taken to overcome the challenge of COVID-19 towards the end of the financial year. As we move forward with strong momentum from our first quarter of this year, we remain optimistic for our current year goals and the long-term success of our business.
Chief Executive Officer
31 July 2020
|Cost of sales||(1,262,337)||-||(1,262,337)||(1,111,399)||-||(1,111,399)|
|Selling and marketing costs||(1,038,295)||-||(1,038,295)||(1,024,868)||-||(1,024,868)|
|Operating loss before interest, tax, depreciation and amortisation||(1,501,664)||(1,196,696)||(2,698,360)|| |
|Amortisation and depreciation||(711,750)||-||(711,750)||(562,355)||-||(562,355)|
|Loss before taxation||(2,505,894)||(1,196,696)||(3,702,590)||(2,095,844)||248,775||(1,847,069)|
|Loss for the year||(2,169,152)||(1,196,696)||(3,365,848)||(1,915,044)||248,775||(1,666,269)|
|Owners of the parent||(2,169,152)||(1,196,696)||(3,365,848)||(1,915,044)||248,775||(1,666,269)|
|Currency translation difference||108,185||-||108,185||129,488||-||129,488|
|Other comprehensive income||108,185||-||108,185||129,488||129,488||129,488|
|Total comprehensive (loss) / gain for the year||(2,060,967)||(1,196,696)||(3,257,663)||(1,785,558)||378,262||(1,536,781)|
|Owners of the parent||(2,060,967)||(1,196,696)||(3,257,663)||(1,785.556)||378,262||(1,536,781)|
|Basic and diluted loss per share||3||(0.76p)||(0.51p)|
|Property, plant and equipment||1,747,338||1,101,959|
|Trade and other receivables||1,938,191||1,137,758|
|Cash and cash equivalents||2,063,173||1,678,079|
|EQUITY AND LIABILITIES|
|Equity attributable to equity holders of the parent company|
|Share-based payment reserve||334,081||291,720|
|Shares to be issued reserve||106,581||106,581|
|Provision for other liabilities and charges||77,697||121,744|
|Trade and other payables||1,452,732||938,556|
|Provision for other liabilities and charges||857,809||38,538|
|Total liabilities and equity||21,759,601||19,200,551|
|Shares to be issued reserve|
|At 1 April 2018||3,290,106||14,869,909||205,820||106,581||4,531,798||675,899||(6,797,962)||16,882,211|
|Loss for the year||-||-||-||-||-||-||(1,666,269)||(1,666,269)|
|Currency translation difference||-||-||-||-||-||129,488||-||129,488|
|Loss and total comprehensive loss for the year||-||-||-||-||-||129,488||(1,666,269)||(1,536,781)|
|At 1 April 2019||3,290,166||14,869,909||291,720||106,581||4,531,798||805,387||(8,464,231)||15,431,330|
|Issue of shares||1,191,664||4,766,657||-||-||-||-||-||5,958,321|
|Share issue costs||-||(275,543)||-||-||-||-||-||(275,543)|
|Proceeds from share issue||1,191,664||4,491,114||-||-||-||-||-||5,682,778|
|Share based compensation||-||-||42,361||-||-||-||-||42,361|
|Loss for the year||-||-||-||-||-||-||(3,365,848)||(3,365,848)|
|Currency translation difference||-||-||-||-||-||108,185||-||108,185|
|Loss and total comprehensive loss for the year||-||-||-||-||-||108,185||(3,365,848)||(3,257,663)|
|Unaudited at 31 March 2020||4,481,830||19,361,023||334,081||106,581||4,531,798||913,572||(11,830,079)||17,898,806|
|Cash flow from operating activities|
|Loss before taxation||(3,702,590)||(1,847,069)|
|Increase in contingent consideration||-||4,744|
|Gain on sale of property, plant and equipment||-||(67,591)|
|Gain on sale of investment||-||(214,965)|
|Increase in inventories||(82,559)||(12,418)|
|(Decrease)/increase in trade and other receivables||(1,289,441)||53,442|
|Increase in trade and other payables||528,375||112,635|
|Increase / (decrease) in provisions||646,432||(202,736)|
|Cash used in operations||(2,853,192)||(1,208,744)|
|Net cash used in operations||(2,877,337)||(1,428,826)|
|Proceeds from the sale of investment||-||214,965|
|Proceeds from sale of property, plant and equipment||-||67,591|
|Payments to acquire property, plant and equipment||(628,112)||(454,215)|
|Payments to acquire licensed IP and patents, and development costs||(587,038)||(740,045)|
|Settlement of contingent and deferred consideration||-||(566,951)|
|Net cash used in investing activities||(1,193,305)||(1,463,401)|
|Net proceeds on issue of ordinary shares||5,682,778||-|
|Net proceeds from Bond issue||-||-|
|Repayment of Bonds||(1,214,176)||(420,325)|
|Repayment of related party loan||-||(43,022)|
|Net cash generated / (used) from financing activities||4,468,602||(463,347)|
|Net increase / (decrease) in cash and cash equivalents||397,960||(3,355,574)|
|Effect of foreign exchange rate changes on the balance of cash held in foreign currencies||(12,866)||11,339|
|Net increase (decrease) in cash and cash equivalents||385,094||(3,344,235)|
|Cash and cash equivalents at the beginning of the financial year||1,678,079||5,022,314|
|Cash and cash equivalents at the end of the financial year||2,063,173||1,678,079|
Page last updated: 31 July 2020
Qualified shippers ensure the product reaches its destination safely within client time and temperature protocols around the globe.